Advertisement

Current Oncology Reports

, 18:1 | Cite as

The Epidemiology of Male Breast Cancer

  • Raina M. Ferzoco
  • Kathryn J. RuddyEmail author
Breast Cancer (B Overmoyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Breast Cancer

Abstract

Male breast cancer is a rare disease, accounting for only 1 % of breast cancer diagnoses in the USA. The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. In this manuscript, we will review known and possible risk factors for male breast cancer, as well as describe the clinical patterns of the disease.

Keywords

Breast neoplasms Male Epidemiology Risk factors 

Notes

Compliance with Ethical Standards

Conflict of Interest

Raina M. Ferzoco and Kathryn J. Ruddy declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

This publication was made possible by CTSA grant numbers UL1 TR000135 and KL2TR000136-09 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Jepson AS, Fentiman IS. Male breast cancer. Int J Clin Pract. 1998;52(8):571–6.PubMedGoogle Scholar
  3. 3.
    Giordano SH et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Society, A.C. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.Google Scholar
  5. 5.
    Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). SEER cancer statistics review, 1975–2011. Bethesda, Maryland: National Cancer Institute.Google Scholar
  6. 6.••
    Cardoso F, Bartlett J, Giordano S, et al., Characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program, in 2014 San Antonio Breast Cancer Symposium 2014, European Organization for Research and Treatmento of Cancer: San Antonio, Texas. This study is the largest collection of male breast cancer biologic samples and clinical characteristics to date. All clinical data and pathology were centrally reviewed for 1473 eligible patients who were treated from 1990 to 2010. The authors report on clinical characteristic and overall survival in male breast cancer patients.Google Scholar
  7. 7.
    Goss PE et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629–39.CrossRefPubMedGoogle Scholar
  8. 8.•
    Masci G et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015;20(6):586–92. In this study, Masci et al. evaluated the cliniopathologic characteristics of 97 male breast cancer specimens and found substantial differences than what it typically seen in female breast cancer. Male breast cancer showed higher rates of hormone receptor positivity and lower rates of HER2 overexpression. Furthermore, higher proliferative index and higher grade were associated with shorter overall survival. CrossRefPubMedGoogle Scholar
  9. 9.
    Gnerlich JL et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837–44.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Chung HC et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J. 1991;32(2):126–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Fox SB et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol. 1992;166(1):13–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 1992;5(6):621–5.Google Scholar
  13. 13.
    Anderson WF et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(2):232–9.CrossRefGoogle Scholar
  14. 14.
    Arslan UY et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Moore J et al. Prognostic indicators in male breast carcinoma. Breast J. 1998;4(4):261–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol. 1992;45(10):942.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Willsher PC et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17(3C):2335–8.PubMedGoogle Scholar
  18. 18.
    Leone JP et al. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Anderson WF et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77–86.CrossRefPubMedGoogle Scholar
  20. 20.
    Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge Jr GW. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol (Meet Abstr). 2009;27:549.Google Scholar
  21. 21.
    Jamy O et al. Male breast cancer: a 24 year experience of a tertiary care hospital in Pakistan. Asian Pac J Cancer Prev APJCP. 2015;16(4):1559–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Albasri A et al. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia. Saudi Med J. 2014;35(12):1489–93.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Salehi A et al. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J. 2011;13(2):99–105.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Tawil AN et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18(1):65–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Ndom P et al. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Miao H et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4381–6.CrossRefGoogle Scholar
  27. 27.
    Chavez-Macgregor M et al. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611–7.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Sineshaw HM et al. Black/White disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(21):2337–44.CrossRefGoogle Scholar
  29. 29.
    O’Malley CD et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94(11):2836–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2002;11(3):253–63.CrossRefGoogle Scholar
  31. 31.
    Ewertz M et al. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Lenfant-Pejovic MH et al. Risk factors for male breast cancer: a Franco-Swiss case–control study. Int J Cancer. 1990;45(4):661–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Brinton LA et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100(20):1477–81.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    D’Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer. 1995;71(6):1359–62.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Rosenblatt KA et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83(12):849–54.CrossRefPubMedGoogle Scholar
  36. 36.
    Casagrande JT et al. A case–control study of male breast cancer. Cancer Res. 1988;48(5):1326–30.PubMedGoogle Scholar
  37. 37.
    Basham VM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res BCR. 2002;4(1):R2.CrossRefPubMedGoogle Scholar
  38. 38.
    Ottini L et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63(2):342–7.PubMedGoogle Scholar
  39. 39.
    Boyd J et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999;53(1):87–91.CrossRefPubMedGoogle Scholar
  40. 40.
    Fackenthal JD et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38(3):159–64.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1434–43.CrossRefGoogle Scholar
  42. 42.
    Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol. 2011;18(7):748–54.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Couch FJ et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13(1):123–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Friedman LS et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Easton DF et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61(1):120–8.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68(2):410–9.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Kwiatkowska E et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(12):4452–9.Google Scholar
  48. 48.
    Thorlacius S et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079–84.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Struewing JP et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet. 1999;65(6):1800–2.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Sverdlov RS et al. Genetic analyses of male breast cancer in Israel. Genet Test. 2000;4(3):313–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Meijers-Heijboer H et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Neuhausen S et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004;108(3):477–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Falchetti M et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat. 2008;110(1):161–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Martinez-Bouzas C et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat. 2007;103(1):111–3.CrossRefPubMedGoogle Scholar
  56. 56.
    Caligo MA et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat. 2004;24(1):100–1.CrossRefPubMedGoogle Scholar
  57. 57.
    Weischer M et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):57–63.CrossRefGoogle Scholar
  58. 58.
    Rizzolo P et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(8):viii75–82.Google Scholar
  59. 59.
    Young IE et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer. 1999;81(1):141–3.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter’s syndrome. J Med Genet. 1971;8(4):460–1.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Hultborn R et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293–7.PubMedGoogle Scholar
  63. 63.
    Newman J. Breast cancer in men and mammography of the male breast. Radiol Technol. 1997;69(1):17–28. quiz 29–36.PubMedGoogle Scholar
  64. 64.
    Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand A Pathol. 1973;81(3):352–8.Google Scholar
  65. 65.
    Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer. 1999;86(5):744–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37(4):246–51.CrossRefPubMedGoogle Scholar
  67. 67.
    Thomas DB et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135(7):734–48.PubMedGoogle Scholar
  68. 68.
    Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125–30.CrossRefPubMedGoogle Scholar
  69. 69.
    Ottini L et al. Male breast cancer. Crit Rev Oncol Hematol. 2010;73(2):141–55.CrossRefPubMedGoogle Scholar
  70. 70.
    Brinton LA et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465.PubMedCentralCrossRefPubMedGoogle Scholar
  71. 71.
    Hsing AW et al. Risk factors for male breast cancer (United States). Cancer Causes Control CCC. 1998;9(3):269–75.CrossRefPubMedGoogle Scholar
  72. 72.
    Brinton LA et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2041–50.CrossRefGoogle Scholar
  73. 73.
    Longcope C et al. Estrogen and androgen dynamics in liver disease. J Endocrinol Investig. 1984;7(6):629–34.CrossRefGoogle Scholar
  74. 74.
    Guechot J et al. Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer. 1988;62(4):760–2.CrossRefPubMedGoogle Scholar
  75. 75.
    Sorensen HT et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93(2):231–3.CrossRefPubMedGoogle Scholar
  76. 76.
    Mills PR et al. Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies? J Clin Pathol. 1982;35(5):541–3.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Goudie BM et al. Breast cancer in women with primary biliary cirrhosis. Br Med J. 1985;291(6509):1597–8.CrossRefGoogle Scholar
  78. 78.
    Wolke AM et al. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med. 1984;76(6):1075–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Floreani A et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999;29(5):1425–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Rubino A, Fissi S, Secreto G. Bilateral breast cancer in a male patient with hepatocellular carcinoma. A case report. Ann Ital Chir. 2008;79(2):117–9.PubMedGoogle Scholar
  81. 81.
    Yoneda S et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol. 2000;95(2):556–7.PubMedGoogle Scholar
  82. 82.
    Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53(4):538–49.CrossRefPubMedGoogle Scholar
  83. 83.
    Thomas E. Original research: men’s awareness and knowledge of male breast cancer. Am J Nurs. 2010;110(10):32–7. 39–40; quiz 41–2.CrossRefPubMedGoogle Scholar
  84. 84.
    Thomas DB et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control CCC. 1994;5(1):9–14.CrossRefPubMedGoogle Scholar
  85. 85.
    Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74(2):371–5.PubMedGoogle Scholar
  86. 86.
    Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med. 2001;39(3):276–85.CrossRefPubMedGoogle Scholar
  87. 87.
    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678–87.CrossRefPubMedGoogle Scholar
  88. 88.
    Bove FJ et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. Environ Health Glob Access Sci Sour. 2014;13:68.Google Scholar
  89. 89.
    Cocco P et al. Case–control study of occupational exposures and male breast cancer. Occup Environ Med. 1998;55(9):599–604.PubMedCentralCrossRefPubMedGoogle Scholar
  90. 90.
    Feychting M et al. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology. 1998;9(4):392–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case–control study. Cancer Causes Control CCC. 1997;8(2):184–91.CrossRefPubMedGoogle Scholar
  92. 92.
    Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337(8743):737.CrossRefPubMedGoogle Scholar
  93. 93.
    Theriault G et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970–1989. Am J Epidemiol. 1994;139(6):550–72.PubMedGoogle Scholar
  94. 94.
    Guenel P et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Ind Med. 1993;50(8):758–64.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Stalsberg H et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control CCC. 1993;4(2):143–51.CrossRefPubMedGoogle Scholar
  96. 96.
    Wick MR et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111(1):59–69.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of OncologyMayo ClinicRochesterUSA

Personalised recommendations